These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9808602)

  • 21. Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients.
    Komatsu H; Yamada S; Iwano H; Okada M; Onozuka H; Mikami T; Yokoyama S; Inoue M; Kaga S; Nishida M; Shimizu C; Matsuno K; Tsutsui H
    Circ J; 2009 Nov; 73(11):2098-103. PubMed ID: 19749478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
    Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL; Park JB; Pu Q
    J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
    J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
    Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
    Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
    Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
    J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Malmqvist K; Ohman KP; Lind L; Nyström F; Kahan T
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):719-26. PubMed ID: 14639093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
    Fogari R; Zoppi A; Mugellini A; Maffioli P; Preti P; Derosa G
    Expert Opin Pharmacother; 2012 Jun; 13(8):1091-9. PubMed ID: 22515416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
    Ke YS; Cao H; Yang T
    Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Hallberg P; Lind L; Michaëlsson K; Karlsson J; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2003 Mar; 21(3):621-4. PubMed ID: 12640257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
    Cuspidi C; Muiesan ML; Valagussa L; Salvetti M; Di Biagio C; Agabiti-Rosei E; Magnani B; Zanchetti A;
    J Hypertens; 2002 Nov; 20(11):2293-300. PubMed ID: 12409969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women.
    Fogari R; Preti P; Zoppi A; Corradi L; Pasotti C; Rinaldi A; Mugellini A
    Am J Hypertens; 2004 Jan; 17(1):77-81. PubMed ID: 14700518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
    Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
    Phipps JA; Wilkinson-Berka JL; Fletcher EL
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):927-34. PubMed ID: 17251496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.